Pharmacy Search
Vertice Login
Menu
close

Medmonitor

An up-to-date timeline of U.S. Food and Drug Administration (FDA) approvals that could potentially impact workers' compensation. These include new drug and indication approvals, new dosages or formulations of existing products, and generics introduced to the market. Click through the interactive timeline below, or select the comprehensive list view.
← Back to Medmonitor

Medication Type: Opioid Use Disorder

Brixadi™ (buprenorphine) extended-release injection

Approval Date: May 2023

Note: New Product

Indicated for the treatment of moderate to severe opioid use disorder (OUD). Brixadi is administered in a healthcare setting and is available in weekly or monthly formulations, each at various dosages

Medication Name

Approval Date

Category

Description

Brixadi™ (buprenorphine) extended-release injection

May 2023

Indicated for the treatment of moderate to severe opioid use disorder (OUD). Brixadi is administered in a healthcare setting and is available in weekly or monthly formulations, each at various dosages

Note: New Product
lockenvelopephone-handsetmagnifiermenucross-circle